This phase IIa clinical study in paediatric and adult patients with mild to moderate atopic dermatitis is designed as a proof-of-concept, multi-centre, randomised, double-blind, vehicle-controlled study with intra-individual comparison of treatments (left-right design so that every patient receives both placebo and treatment).
The main objectives of the study are to assess the efficacy of the Cyclatop© topical solution compared to a placebo topical solution in treating patients with mild to moderate atopic dermatitis and to evaluate the safety and the tolerability in patients with mild to moderate AD. According to Benjamín Santos, senior Project Manager at Spherium top-line results are expected during the third quarter of 2018.
Spherium is developing Cyclatop© under an exclusive license from Bionanoplus, a drug-delivery company located in Navarre (Spain), and based on the company’s intellectual property.
ABG IP is proud to have collaborated with Spherium Biomed and with Bionanoplus in the IP protection of SP14019 and other products in the companies’ pipeline.
